The UAE has recently unveiled its first comprehensive laboratory called OncoHelix-CoLab, specializing in advanced molecular and transplant diagnostics, cancer genomic profiling, and immunology testing. This state-of-the-art facility, located at a leading private hospital in the UAE capital, offers sophisticated tests using advanced technologies like next-generation sequencing (NGS), droplet digital PCR, and multi-colour flow cytometry. The lab aims to streamline the diagnostic process by eliminating the need for sending samples abroad, reducing costs, and expediting results, ultimately improving patient care and developing tailored healthcare solutions for the population.
Partnering with Canada-based OncoHelix, Burjeel Holdings has established this cutting-edge laboratory at Burjeel Medical City (BMC) in Abu Dhabi. OncoHelix is known for its precision diagnostics and specialized molecular and immune profile testing. The lab, which was inaugurated by officials from Canada, Burjeel Holdings, and OncoHelix, is the first of its kind in the UAE to offer international expertise to meet local healthcare needs. Dr. Meer Taher Shabani Rad, chief medical officer of OncoHelix-CoLab, highlighted the facility’s ability to provide in-depth insights into disease pathology at a molecular level, addressing unique healthcare challenges in the UAE and the Middle East.
By reducing dependence on international services and offering unique medical solutions, this laboratory contributes to the UAE’s goal of achieving healthcare self-reliance and promoting medical tourism. With strong capabilities in critical clinical areas, the lab aims to serve as a center for research, development, and innovation, advancing treatment options and strengthening the healthcare ecosystem. Additionally, the lab plans to enhance local expertise in esoteric diagnostics by providing clinical training and fellowship programs in molecular and transplant diagnostics, further building capacity in advanced diagnostics.
The groundbreaking partnership between Burjeel Holdings and OncoHelix is set to revolutionize diagnostics through research and innovation, leveraging cutting-edge technologies to drive advanced translational research and evidence-driven precision diagnostics. This collaboration aims to improve patient outcomes in the Middle East and North Africa region by offering tailored healthcare solutions. By nurturing talent and expertise in advanced diagnostics, the lab ensures that the local healthcare industry remains at the forefront of medical advancements and innovation, supporting the overall growth and development of the sector.
The OncoHelix-CoLab laboratory’s advanced capabilities, including cancer genomic profiling and specialized immunology testing, enable it to offer a comprehensive suite of diagnostic services that provide valuable insights into disease pathology at a molecular level. This innovative approach to diagnostics allows for the development of personalized healthcare solutions tailored to the unique needs of the UAE and the wider Middle East region. By harnessing the latest technologies and international expertise, the lab aims to drive advancements in precision medicine and ultimately improve patient outcomes through evidence-based diagnostics and treatment strategies.
In addition to its diagnostic capabilities, the OncoHelix-CoLab laboratory plays a pivotal role in strengthening the UAE’s healthcare ecosystem by reducing reliance on international services and enhancing local capacity in advanced diagnostics. By offering clinical training and fellowship programs in molecular and transplant diagnostics, the lab contributes to the development of talent and expertise in esoteric diagnostics, further bolstering the region’s healthcare infrastructure. This initiative aligns with the UAE’s strategic priorities of achieving self-reliance in healthcare, driving medical tourism, and advancing research and innovation in the healthcare sector.
